positron emission tomography

December 12, 2018

Phase 3 Trial Testing New Imaging Agent for Prostate Cancer Detection Doses First Patient

News

A Phase 3 trial evaluating Progenics Pharmaceuticals‘ new imaging agent to help detect prostate cancer recurrence has begun dosing participants. The agent, called PyL (18F-DCFPyl), is a tracing substance composed of the prostate ... Read more

December 6, 2018

New Imaging Agent Better at Detecting Signs of Prostate Cancer Recurrence, Study Reports

News

A new imaging agent for use in positron emission tomography (PET) is better than conventional imaging at detecting cancer location and spread in prostate cancer patients suspected of cancer recurrence, ... Read more

June 13, 2016November 18, 2016

Studies That Led to FDA Approval of Axumin as Prostate Cancer Imaging Agent Presented at SNMMI 2016

News

Blue Earth Diagnostics Inc. of Burlington, Massachusetts, announced that it is presenting results from studies that led to the recent U.S. Food and Drug Administration (FDA) approval of its molecular imaging agent Axumin (fluciclovine ... Read more

June 6, 2016June 6, 2016

FDA Approves Diagnostic Imaging Agent Axumin for Recurrent Prostate Cancer

News

The US Food and Drug Administration (FDA) has recently approved Axumin, an injectable radioactive diagnostic agent used to detect recurrent prostate cancer. Axumin (marketed by Blue Earth Diagnostics, Ltd., Oxford, ... Read more